<div id="readability-page-1">Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS […]</div>

IBBQ

TBXU

<p>Daiwa has downgraded Pfizer (PFE) to a neutral rating after the company's Q4 2025 earnings report, which showed $17.6 billion in revenue and $0.66 EPS, exceeding expectations. Bernstein, however, maintained its Market Perform rating and $30 price target for Pfizer, highlighting it as a promising low-cost stock to buy.</p>

- Pfizer Inc. reported Q4 2025 earnings of $17.6 billion in revenue and $0.66 EPS, exceeding expectations.  
- Bernstein maintained its Market Perform rating and $30 price target for the company.  
- The strong financial results contribute to Pfizer being viewed as a promising low-cost stock to consider for investment.

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VG Health

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

Pfizer

Daiwa downgrades Pfizer (PFE) to neutral following full-year 2025 earnings